June 7, 2021 10:15 AM EDTUpdated June 7, 11:49 PM

FDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field

Jason Mast

Editor

Bluebird bio announced that the FDA has lifted its holds on clinical trials for their gene therapies for sickle disease and beta-thalassemia, ending a 4 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field

Jason Mast

Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

FDA lets blue­bird re­sume tri­als for sick­le cell gene ther­a­py af­ter can­cer scare, but big ques­tions linger over field

Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA lets bluebird resume trials for sickle cell gene therapy after cancer scare, but big questions linger over field